AbbVie Net Income 2010-2018 | ABBV

AbbVie annual/quarterly net income history and growth rate from 2010 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • AbbVie net income for the quarter ending September 30, 2018 was $2.747B, a 68.42% increase year-over-year.
  • AbbVie net income for the twelve months ending September 30, 2018 was $7.565B, a 13.79% increase year-over-year.
  • AbbVie annual net income for 2017 was $5.309B, a 10.82% decline from 2016.
  • AbbVie annual net income for 2016 was $5.953B, a 15.73% increase from 2015.
  • AbbVie annual net income for 2015 was $5.144B, a 189.97% increase from 2014.
AbbVie Annual Net Income
(Millions of US $)
2017 $5,309
2016 $5,953
2015 $5,144
2014 $1,774
2013 $4,128
2012 $5,275
2011 $3,433
2010 $4,178
2009 $4,637
AbbVie Quarterly Net Income
(Millions of US $)
Q3 2018 $2,747
Q2 2018 $1,983
Q1 2018 $2,783
Q4 2017 $52
Q3 2017 $1,631
Q2 2017 $1,915
Q1 2017 $1,711
Q4 2016 $1,391
Q3 2016 $1,598
Q2 2016 $1,610
Q1 2016 $1,354
Q4 2015 $1,517
Q3 2015 $1,239
Q2 2015 $1,366
Q1 2015 $1,022
Q4 2014 $-810
Q3 2014 $506
Q2 2014 $1,098
Q1 2014 $980
Q4 2013 $1,128
Q3 2013 $964
Q2 2013 $1,068
Q1 2013 $968
Q4 2012 $1,540
Q3 2012 $1,585
Q2 2012 $1,267
Q1 2012 $883
Q4 2011 $1,157
Q3 2011 $13
Q2 2011 $1,540
Q1 2011 $723
Q4 2010 $0
Q4 2009 $0
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $132.702B $28.216B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.162B 18.20
Pfizer (PFE) United States $259.069B 14.60
Novartis AG (NVS) Switzerland $204.655B 17.49
Merck (MRK) United States $201.163B 17.43
Eli Lilly (LLY) United States $119.057B 20.93
Sanofi (SNY) France $112.613B 13.94
Novo Nordisk (NVO) Denmark $107.980B 17.54
AstraZeneca (AZN) United Kingdom $105.090B 13.05
GlaxoSmithKline (GSK) United Kingdom $102.669B 13.80
Bristol-Myers Squibb (BMY) United States $85.837B 14.14